The Transparency Directive — Is it Working? M. L. Burstall The Transparency Directive 15 November 2012 Pages: 1 - 8
Price Regulation, Industry Structure and Innovation Lacy Glenn Thomas III Comparison of Pharmaceutical Industries 15 November 2012 Pages: 9 - 12
Rising Research and Development Costs for New Drugs in a Cost Containment Environment Joseph A. Di Masi Research and Development Costs in Cost Containment 15 November 2012 Pages: 13 - 20
The Reimbursement Factor in Pharmaceutical Regulation Sheila R. Shulman Reimbursement in Pharmaceutical Regulation 15 November 2012 Pages: 21 - 27
US Medicaid Drug Formularies William J. MooreRobert J. Newman Medicaid Drug Formularies 15 November 2012 Pages: 28 - 31
The Effect of Medicaid Formularies on the Availability of New Drugs Henry G. GrabowskiStuart O. SchweitzerS. Renee Shiota Medicaid Formularies and New Drug Availability 15 November 2012 Pages: 32 - 40
Clinical Aspects of Therapeutic Substitution Richard A. Levy Clinical Aspects of Therapeutic Substitution 15 November 2012 Pages: 41 - 44
Improving the Quality and Cost—Effectiveness of Prescribing Jerry Avorn Improving Prescribing Practices 15 November 2012 Pages: 45 - 48
Comparative Potency and Dissolution Performance of Internationally Available Piroxicam Products Joseph A. Barone Potency and Dissolution of Piroxicam Products 15 November 2012 Pages: 49 - 52
Challenging Official Health Cost Estimates Aldona RobbinsGary Robbins Challenging Health Cost Estimates 15 November 2012 Pages: 53 - 60
Australian Guidelines for Cost—Effectiveness Studies of Pharmaceuticals Michael Drummond Cost—Effectiveness of Pharmaceuticals 15 November 2012 Pages: 61 - 69
Is Parallel Trade in Medicines Compatible with the Single European Market? Ian Senior Parallel Trade in Medicines in Europe 15 November 2012 Pages: 70 - 76